Skip to content

Elderly Primary Insomnia Polysomnographic Study (0928-002)(TERMINATED)

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 30-Night Polysomnographic Study of MK0928 in Elderly Patients With Primary Insomnia

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00094666
Enrollment
465
Registered
2004-10-22
Start date
2004-11-30
Completion date
2007-03-31
Last updated
2015-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Insomnia

Brief summary

The purpose of the study is to test the safety and effectiveness of an Investigational Drug on insomnia in the elderly.

Interventions

DRUGMK0928, gaboxadol / Duration of Treatment - 6 weeks
DRUGComparator: placebo / Duration of Treatment - 6 weeks

Sponsors

H. Lundbeck A/S
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Elderly patients with a diagnosis of primary insomnia and in good physical and mental health

Design outcomes

Primary

MeasureTime frame
Amount of time spent awake and time to fall asleep at night after two days

Secondary

MeasureTime frame
Amount of time spent awake and time to fall asleep at night after 30 days
Amount of deep sleep after two days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026